Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-341A3835-D61E-4256-9D7D-38AFE7673AFD_2_en-US
DOI: https://doi.org/10.31003/USPNF_M14280_02_01
DOI Ref: mf784

Cephalexin



$C_{16}H_{17}N_3O_4S \cdot H_2O$ 365.40
$C_{16}H_{17}N_3O_4S$ 347.40

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-methyl-8-oxo-, monohydrate, [6*R*-[6α,7β (*R**)]]-;
(6*R*,7*R*)-7-[(*R*)-2-Amino-2-phenylacetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate CAS RN®: 23325-78-2; UNII: OBN7UDS42Y.

Anhydrous CAS RN®: 15686-71-2; UNII: 5SFF1W6677.

DEFINITION

Cephalexin has a potency of NLT 950 µg/mg and NMT 1030 µg/mg of $C_{16}H_{17}N_3O_4S$, calculated on the anhydrous basis.

IDENTIFICATION

Change to read:

• **A.** ▲**Spectroscopic Identification Tests ⟨197⟩, *Infrared Spectroscopy*: 197K**▲ (CN 1-May-2020)

• **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

ASSAY

• **Procedure**

Mobile phase: 0.985 g/L of sodium-1-pentanesulfonate in a mixture of acetonitrile, methanol, triethylamine, and water (20:10:3:170), adjusted with phosphoric acid to a pH of 3.0 ± 0.1

Standard stock solution: 1 mg/mL of USP Cephalexin RS in water

Standard solution: 0.4 mg/mL of cephalexin in *Mobile phase* from *Standard stock solution*

Sample stock solution: 1 mg/mL of Cephalexin in water

Sample solution: 0.4 mg/mL of Cephalexin in *Mobile phase* from *Sample stock solution*

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 25-cm; packing L1 of low acidity

Flow rate: 1.5 mL/min

Injection size: 20 µL

System suitability

Sample: *Standard solution*

Suitability requirements

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the quantity, in µg, of cephalexin ($C_{16}H_{17}N_3O_4S$) per mg of the Cephalexin taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of USP Cephalexin RS in the *Standard solution* (mg/mL)

C_U = concentration of Cephalexin in the *Sample solution* (mg/mL)

P = potency of cephalexin in USP Cephalexin RS (µg/mg)

Acceptance criteria: 950–1030 µg/mg on the anhydrous basis

IMPURITIES

Organic Impurities

- **Procedure 1**

Solution A: Dissolve 1 g of sodium 1-pentanesulfonate in a mixture of 1000 mL of water and 15 mL of triethylamine. Adjust with phosphoric acid to a pH of 2.5 ± 0.1.

Solution B: Dissolve 1 g of sodium 1-pentanesulfonate in a mixture of 300 mL of water and 15 mL of triethylamine. Adjust with phosphoric acid to a pH of 2.5 ± 0.1, and add 350 mL of acetonitrile and 350 mL of methanol.

Mobile phase: See the gradient table below.

Time (min)	Solution A (%)	Solution B (%)
0	100	0
1	100	0
33.3	0	100
34.3	0	100

Diluent: 18 mg/mL of monobasic potassium phosphate in water

Standard solutions: 0.08 mg/mL and 0.16 mg/mL of cephalexin ($C_{16}H_{17}N_3O_4S$) from USP Cephalexin RS in *Diluent*, taking into account the stated potency of the USP Cephalexin RS

Sample solution: 5 mg/mL of Cephalexin in *Diluent*

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 25-cm; packing L1 of low acidity

Flow rate: 1 mL/min

Injection size: 20 µL

Analysis

Samples: *Standard solutions* and *Sample solution*

Plot the responses of the cephalexin peaks from the *Standard solutions* versus their concentrations, calculated on the anhydrous basis, in mg/mL, and draw a straight line through the two points and zero. From the line and the peak responses of the *Sample solution*, determine the concentration, I, in mg/mL, of each cephalexin-related substance of the *Sample solution* other than the cephalexin peak.

Calculate the percentage of each cephalexin-related substance:

$$\text{Result} = I/C \times 100$$

I = concentration of each cephalexin-related substance in the *Sample solution* as determined from the calibration curve (mg/mL)

C = concentration of cephalexin from the *Sample solution* (mg/mL)

Acceptance criteria

Individual impurities: NMT 1.0% of any individual cephalexin-related substance

Total impurities: NMT 5.0%

- **Procedure 2: Dimethylaniline ⟨223⟩:** Meets the requirement

SPECIFIC TESTS

- **Optical Rotation, *Specific Rotation*⟨781S⟩:** +149° to +158°

Sample solution: 5 mg/mL, in pH 4.4 neutralized phthalate buffer (see *Reagents, Indicators, and Solutions—Buffer Solutions*)

- **Crystallinity ⟨695⟩:** Meets the requirements
- **pH ⟨791⟩:** 3.0–5.5, in an aqueous suspension containing 50 mg/mL
- **Water Determination, *Method I*⟨921⟩:** 4.0%–8.0%

ADDITIONAL REQUIREMENTS

- **Packaging and Storage:** Preserve in tight containers.

- **USP Reference Standards ⟨11⟩**
  USP Cephalexin RS

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
CEPHALEXIN	Documentary Standards Support	SM12020 Small Molecules 1

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 43(6)

Current DocID: GUID-341A3835-D61E-4256-9D7D-38AFE7673AFD_2_en-US
DOI: https://doi.org/10.31003/USPNF_M14280_02_01
DOI ref: mf784